5.01.19
14 min. read

Approximating Livongo Health’s S-1

In this article:

Digital health company Livongo Health is expected to go public later this year. In anticipation of the company’s S-1 filing, E&O has put together this 3,600-word report, including annual revenue figures, quarterly adoption metrics, regulatory mishaps, acquisitions, growth strategies, predictions and much, much more.

Paying Subscribers Only

It's a good one, too.
This digital health research is for paying Exits & Outcomes subscribers only. Subscribe now to read this article, get the weekly newsletter, and receive unrestricted access to past and future research from the Exits & Outcomes archives. Smash the link above or below to subscribe yourself -- or head over to our pricing page to subscribe your team or your whole company!

Less than five years ago, longtime healthcare IT executive Glen Tullman took the stage at TechCrunch Disrupt 2014 and announced the launch of his new startup, a diabetes-focused company called Livongo Health. Incredibly, Livongo launched with an FDA-cleared, cellular-enabled glucose meter, a clinical validation study already underway at the University of Massachusetts, and a handful of paying customers that included Office Depot. On the day it officially launched the company had already achieved milestones that prove elusive to many health startups.

×

Become a Subscriber

Get the subscribers-only, weekly newsletter and exclusive content.

Recent Articles